wzb117 and fasentin

wzb117 has been researched along with fasentin* in 1 studies

Other Studies

1 other study(ies) available for wzb117 and fasentin

ArticleYear
Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:5

    Targeting glucose metabolism is a promising way to interfere with tumor cell proliferation and survival. However, controversy exists about the specificity of some glucose metabolism targeting anticancer drugs. Especially the potency of STF-31 has been debated. Here, we aimed to assess the impact of the glucose transporter (GLUT) inhibitors fasentin and WZB117, and the nicotinamide phosphoribosyltransferase (NAMPT) inhibitors GMX1778 and STF-31 on tumor cell proliferation and survival, as well as on glucose uptake.. Tumor-derived A172 (glioblastoma), BHY (oral squamous cell carcinoma), HeLa (cervix adenocarcinoma), HN (head neck cancer), HT-29 (colon carcinoma) and MG-63 (osteosarcoma) cells were treated with fasentin, WZB117, GMX1778 and STF-31. Proliferation rates and cell viabilities were assessed using XTT, crystal violet and LDH assays. mRNA and protein expression of GLUT1 and NAPRT were assessed using qPCR and Western blotting, respectively. The effects of inhibiting compounds on glucose uptake were measured using [. Stimulation of tumor-derived cells with the different inhibitors tested revealed a complex pattern, whereby proliferation inhibiting and survival reducing concentrations varied in [. Our data reveal a dual mode of action of STF-31, serving either as a NAMPT or as a GLUT inhibitor, whereby the latter seems to be apparent only at higher STF-31 concentrations. The molecular basis of such a dual function and its appearance in compounds previously designated as NAMPT-specific inhibitors requires further investigation.

    Topics: Anilides; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glucose; Glucose Transport Proteins, Facilitative; Humans; Hydroxybenzoates; NAD; Nicotinamide Phosphoribosyltransferase; Pyridines

2018